Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Agios Pharmaceuticals (AGIO) Revenue (2016 - 2025)

Agios Pharmaceuticals (AGIO) has disclosed Revenue for 12 consecutive years, with $20.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Revenue rose 86.09% year-over-year to $20.0 million, compared with a TTM value of $54.0 million through Dec 2025, up 48.03%, and an annual FY2025 reading of $54.0 million, up 48.03% over the prior year.
  • Revenue was $20.0 million for Q4 2025 at Agios Pharmaceuticals, up from $12.9 million in the prior quarter.
  • Across five years, Revenue topped out at $20.0 million in Q4 2025 and bottomed at $832000.0 in Q1 2022.
  • Average Revenue over 4 years is $8.2 million, with a median of $7.8 million recorded in 2023.
  • The sharpest move saw Revenue surged 574.16% in 2023, then rose 6.56% in 2025.
  • Year by year, Revenue stood at $4.3 million in 2022, then surged by 64.8% to $7.1 million in 2023, then skyrocketed by 51.06% to $10.7 million in 2024, then soared by 86.09% to $20.0 million in 2025.
  • Business Quant data shows Revenue for AGIO at $20.0 million in Q4 2025, $12.9 million in Q3 2025, and $12.5 million in Q2 2025.